ACS Launches Major Epidemiology Study

Publication
Article
Oncology NEWS InternationalOncology NEWS International Vol 16 No 6
Volume 16
Issue 6

The American Cancer Society (ACS) is launching a 20-year cancer epidemiology study of 500,000 cancer-free adults across the United States. Cancer Prevention Study 3 (CPS-3) will enroll geographically and ethnically diverse participants at 64 of the 4,800 ACS-sponsored Relay for Life events taking place across the country in 2007, and it will continue the accrual process at select Relay events through 2011.

ATLANTA—The American Cancer Society (ACS) is launching a 20-year cancer epidemiology study of 500,000 cancer-free adults across the United States. Cancer Prevention Study 3 (CPS-3) will enroll geographically and ethnically diverse participants at 64 of the 4,800 ACS-sponsored Relay for Life events taking place across the country in 2007, and it will continue the accrual process at select Relay events through 2011. Relay for Life events are "fun run/walk" overnight fundraisers held at schools, fairgrounds, or parks to celebrate survivorship and support ACS research and programs.

Participants in CPS-3 must be between 30 and 65 years of age, must never have been diagnosed with cancer, and must agree to make a long-term commitment to the study. Enrollees complete a brief study questionnaire; investigators measure their waistline and take a small blood sample. Then, for at least 20 years, CPS-3 enrollees will be tracked through questionnaires mailed every few years, identifying and studying factors associated with cancer occurrence or prevention.

The investigators will collect biological specimens from the participants; assess their dietary, lifestyle, and environmental exposures; and conduct active follow-up to discover if and when study participants develop cancer.

Newsletter

Stay up to date on recent advances in the multidisciplinary approach to cancer.

Recent Videos
4 experts in this video
2 experts in this video
2 experts in this video
4 experts in this video
Ongoing studies seek to evaluate immunotherapy in earlier lines of therapy for patients with early-stage Hodgkin lymphoma.
Strict inclusion criteria may disproportionately exclude racial minority populations from participating in breast cancer trials.
A paucity of prospective, well-vetted data to guide therapy in patients with rare lymphomas may result in a reliance on expert consensus guidelines.
Related Content